TITLE

Dalcetrapib

PUB. DATE
May 2010
SOURCE
Drugs in R&D;2010, Vol. 10 Issue 1, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific profile of this new compound.
ACCESSION #
66916404

 

Related Articles

  • Roche and Japan Tobacco collaborate over dyslipidemia therapy.  // PharmaWatch: Biotechnology;December2004, Vol. 3 Issue 12, p19 

    Reports the licensing agreement between Roche Pharmaceuticals and Japan Tobacco Inc. for the late-stage development and commercialization of an innovative cholesterol modifying agent, a potential therapy for treatment of dyslipidemia. Terms of the agreement; Benefits for both parties; Prevalence...

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.

  • MDRNA signs licensing agreement with Roche.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18 

    The article reports on the signing of a licensing agreement by MDRNA Inc. and Roche Pharmaceuticals. The licensing agreement is consistent to which Roche will get a non-exclusive license to a portion of MDRNA's technology platform for the development of ribonucleic acid interference-based...

  • Roche pulls out of alliance with Basilea for new antibiotic.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p17 

    Reports on the strategic alliance of Roche Pharmaceutical Co. with Basilea Pharmaceutica Ltd. for the development of new antibiotic drug. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for pharmaceutical biotechnology industry.

  • Roche and Aileron Therapeutics Expand Collaboration for Stapled Peptide Drugs.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p602 

    The article reports on initiation of a program by Roche to expand its collaboration with Aileron Therapeutics Inc. It notes that the program aims to collaborate on the discovery, development and commercialization of Stapled Peptide drugs. It adds that the 1.1-billion-dollar drug development...

  • Other News To Note.  // BioWorld Today;12/13/2010, Vol. 21 Issue 239, p4 

    This section offers news briefs on the biotechnology industry including the license agreement signed between Serodus A/S and Roche AG and the finalization of a buyout offer by Spencer Pharmaceuticals Inc. of Al-Dorra Group.

  • Life Sciences in brief.  // Chemical Market Reporter;12/5/2005, Vol. 268 Issue 19, p37 

    The article presents news briefs related to the life sciences industry. IDM Pharma Inc. has agreed to sell specific assets of its infectious disease programs and other assets to Pharmexa AS for $12 million to focus on its five clinical-stage cancer programs. A biologics license application was...

  • Start-up Afferent Licenses Roche Pain Drug Program. Hollingsworth, Catherine // BioWorld Today;12/17/2009, Vol. 20 Issue 242, p1 

    This article reports on the license agreement signed by Swiss drugmaker F. Hoffmann-La Roche AG with Afferent Pharmaceuticals for its P2X3 receptor program aimed at chronic pain. Start-up Afferent also closed a Series A financing deal in relation to the Roche agreement. Afferent co-founder...

  • SurModics signs licensing and development agreement with Roche and Genentech.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p25 

    The article reports on the licensing and development agreement signed by drug delivery and surface modification technologies provider SurModics Inc. with Roche and Genentech Inc. The agreement allows Roche and Genentech with an exclusive license to use SurModics's proprietary biodegradable...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics